Padeliporfin
DRACPC ID DRACPC0024
Active Ingredients Padeliporfin
Description A vascular-acting photosensitizer consisting of a water-soluble, palladium-substituted bacteriochlorophyll derivative with potential antineoplastic activity. Upon administration, paldeliporfin is activated locally when the tumor bed is exposed to low-power laser light; reactive oxygen species (ROS) are formed upon activation and ROS-mediated necrosis may occur at the site of interaction between the photosensitizer, light and oxygen. Vascular-targeted photodynamic therapy (VTP) with padeliporfin may allow tumor-site specific cytotoxicity while sparing adjacent normal tissues.
Synonyms Palladium-Bacteriochlorophyll Derivative WST11; WST11; Padeliporfin
Type Small Molecule
Disease Low Risk Prostate Cancer
Classification
Peptide and derivative Photosensitizing Agents
Structure Information
Molecular Formula C37H43N5O9PdS
Molecular Weight 840.3
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name palladium(II) (7S,8S,17R,18R)-13-acetyl-7-(2-carboxyethyl)-18-ethyl-5-(2-methoxy-2-oxoethyl)-2,8,12,17-tetramethyl-3-((2-sulfoethyl)carbamoyl)-7H,8H,17H,18H-porphyrin-21,23-diide
InChI InChI=1S/C37H45N5O9S.Pd/c1-8-22-17(2)25-16-30-33(21(6)43)19(4)27(40-30)14-26-18(3)23(9-10-31(44)45)35(41-26)24(13-32(46)51-7)36-34(37(47)38-11-12-52(48,49)50)20(5)28(42-36)15-29(22)39-25;/h14-18,22-23H,8-13H2,1-7H3,(H5,38,39,40,41,42,43,44,45,47,48,49,50);/q;+2/p-2/t17-,18+,22-,23+;/m1./s1
InChI_Key MZRDSGWDVDESRC-VNWQTDIGSA-L
SMILES [H][C@]1(C2=N/C([C@]1(C)[H])=C\C3=C(C(C(C)=O)=C([N-]3)/C=C4N=C([C@](CC)([C@]\4(C)[H])[H])/C=C5[N-]/C(C(C(NCCS(=O)(O)=O)=O)=C\5C)=C2/CC(OC)=O)C)CCC(O)=O.[Pd+2]
External Codes
PubChem CID 76961489
DrugBank Accession Number DB15575
NCI Thesaurus Code C78481
UNII EEO29FZT86 GSRS
CAS 759457-82-4
Drug approval
Drug indication
Padeliporfin is indicated for the treatment of adults with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy greater than or equal to 10 years.
| Drug Name | Strength | Dosage Form/Route | Company | Marketing Status | Drug ID | Approval year |
|---|---|---|---|---|---|---|
| Tookad | unknown | Injectable; Intravenous | Steba Biotech S.A | Prescription | EMEA/H/C/004182 | 2017 |
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT04620239 | Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer | Transitional Cell Cancer of Renal Pelvis and Ureter | Phase 3 | Treatment |
| NCT03617003 | Phase I Study of WST11 Phototherapy for Upper Tract Urothelial Carcinoma | Upper Tract Urothelial Carcinoma | Phase 1 | Treatment |
| NCT00975429 | Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer | Prostate Cancer | Phase 2 | Treatment |
| NCT01573156 | Vascular Targeted Photodynamic Therapy With WST11 for T1a Renal Tumours. PHASE IIa Histological Follow up Trial | Renal Cancer | Phase 1/2 | Treatment |
| NCT03133650 | A Phase I Trial of Vascular-Targeted Photodynamic Therapy in Esophagogastric Cancer Patients With Moderate to Severe Dysphagia | Esophagogastric Cancer; Moderate to Severe Dysphagia | Phase 1 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
